eRace Cancer

Erasca is a clinical-stage precision oncology company dedicated to developing therapies that comprehensively shut down the RAS/MAPK pathway, one of the most commonly mutated signaling cascades in cancer. The company's name is a portmanteau of its mission to "erase cancer," and its pipeline is designed to target this pathway at multiple nodes to overcome resistance mechanisms. Erasca's lead programs include ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-RAS inhibitor, following a strategic pipeline prioritization in 2024. The company leverages a modality-agnostic approach to identify and develop the most effective inhibitors for various RAS-driven malignancies.